NGM Biopharmaceuticals, Inc. (NGM)
Chart Events
Performance Outlook
| Previous Close | 16.64 |
| Open | 16.45 |
| Bid | 16.61 x 1200 |
| Ask | 16.64 x 1000 |
| Day's Range | 16.33 - 16.91 |
| 52 Week Range | 10.49 - 27.25 |
| Volume | |
| Avg. Volume | 475,296 |
| Market Cap | 1.336B |
| Beta (5Y Monthly) | 1.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.61 |
| Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NGM
Related Research
- NGM Biopharmaceuticals, Inc.The Argus High-Yield Model PortfolioValue stocks -- a market segment that includes high-yield stocks -- are outperforming growth stocks in 2022 for the first time since 2016. Indeed, for the past decade, the performance record has favored growth. In nine of the past 10 years, growth stocks have topped value stocks. But the tide may be turning. The rollout of COVID-19 vaccines has given a lift to some of the cyclical companies (energy companies and regional banks) that have lagged in recent quarters, and value stocks have kept up the pace with growth stocks in the past year. Now, the Federal Reserve lifting interest rates to fend off inflation, which will likely cap multiple expansion for growth companies. Regardless, the value sector is the place to achieve income. The current yield on the iShares Russell 1000 Value Index ETF is 2.1%, compared to the 0.8% current yield on the iShares Russell 1000 Growth Index ETF. For our High-Yield Theme Model Portfolio, we are seeking stocks with yields of at least 3.0%. This moves us deep into the value segment of the market.RatingFair ValueEconomic Moat23 hours agoArgus Research
- GlobeNewswire
NGM Bio Announces Presentations Featuring Updated Findings from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the European Society of Medical Oncology (ESMO) Annual Congress and the Ongoing Phase 1b Trial of NGM120 in Patients with Advanced Pancreatic Cancer at the American Association for Cancer Research (AACR) Special Conference: Pancreatic Cancer
Poster presentation at upcoming ESMO Annual Congress to highlight analysis of subgroup of patients with prostate cancer in NGM120 Phase 1a trialShort-talk presentation at upcoming AACR Special Conference: Pancreatic Cancer to highlight analysis of patients with advanced pancreatic cancer in NGM120 Phase 1b trial SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transfo
- Simply Wall St.
The NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Analysts Have Been Trimming Their Sales Forecasts
One thing we could say about the analysts on NGM Biopharmaceuticals, Inc. ( NASDAQ:NGM ) - they aren't optimistic...
- Zacks
NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -7.27% and 37.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
